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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is amongst the deadliest of human cancers, due to its late diagnosis as well as its
intense resistance to currently available therapeutics. To identify mechanisms as to why PDAC are refractory to DNA
damaging cytoxic chemotherapy and radiation, we performed a global interrogation of the DNA damage response of PDAC.
We find that PDAC cells generally harbor high levels of spontaneous DNA damage. Inhibition of Non-Homologous End
Joining (NHEJ) repair either pharmacologically or by RNAi resulted in a further accumulation of DNA damage, inhibition of
growth, and ultimately apoptosis even in the absence of exogenous DNA damaging agents. In response to radiation, PDAC
cells rely on the NHEJ pathway to rapidly repair DNA double strand breaks. Mechanistically, when NHEJ is inhibited there is
a compensatory increase in Homologous Recombination (HR). Despite this upregulation of HR, DNA damage persists and
cells are significantly more sensitive to radiation. Together, these findings support the incorporation of NHEJ inhibition into
PDAC therapeutic approaches, either alone, or in combination with DNA damaging therapies such as radiation.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains the fourth
leading cause of cancer mortality in the United States [1], and is
characterized by an intense resistance to chemotherapy and
ionizing radiation (IR). Because of this, the majority of patients will
succumb to their disease in less than one year and novel
therapeutic approaches are clearly needed. Genomic instability
is one of the hallmarks of cancer [2] and consistent with this we
and others have shown that pancreatic cancers display extremely
high levels of genomic alterations [3]. Furthermore, pancreatic
cancers are profoundly resistant to DNA damaging therapies such
as cytotoxic chemotherapy and radiation [4]. However, the
biological significance of genomic instability in this disease and
how this may impact the response to DNA damaging therapies is
relatively unexplored.
Double stranded breaks (DSBs), induced by radiation or other
DNA damaging agents, are believed to be the most hazardous
DNA lesions that threaten cellular survival. In response to ionizing
radiation, DSBs are detected by the Mre11–Rad50–Nbs1 complex
(MRN complex) and Ku70/Ku80 complexes which rapidly
activate ataxia telangiectasia mutated (ATM) and DNA-PK
respectively [5]. Activation of these kinases induces a series of
cellular events including phosphorylation of cell cycle checkpoint
proteins and the initiation of the DNA repair process. Histone
H2AX, an important substrate of ATM and DNA-PK, is
phosphorylated on serine 139 (referred to as cH2AX), which
forms foci on DSB sites associated with other repair factors [6].
Two major pathways exist to repair DSBs -homologous
recombination (HR) and non-homologous end-joining (NHEJ)
[7,8]. HR-directed repair requires an homologous chromosome or
a sister chromatid as a template to repair DNA with high fidelity,
and therefore it mainly occurs in S- and G2- phases of the cell
cycle when the template is available. In contrast to HR, NHEJ
repairs DSB by ligation of two DNA ends following DNA end
processing. The end processing often leads to loss of nucleotides
and makes NHEJ error-prone [9]. NHEJ is active throughout the
cell cycle. Therefore, cell cycle stage and the nature of DNA ends
are two determinants of repair choices between HR and NHEJ
[7,10]. In addition, DNA-PK activity itself has been implicated in
the inhibition of HR [11,12]. Importantly, cancer cells often show
abnormalities in the DNA damage response and defects in DNA
repair which may correlate with altered expression of repair
proteins. For example, higher expression of the NHEJ proteins,
DNA-PK and Ku70/80 has been reported in cancer cell lines
[13,14,15,16] However, the DNA damage response and DNA
repair in PDAC cells remains relatively unexplored.
Here we investigated the importance of DNA repair in PDAC
biology and find that PDAC cells harbor elevated levels of basal
DNA damage. Inhibition of NHEJ results in increased DNA
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NHEJ inhibition, HR is upregulated but cells are unable to repair
DNA damage efficiently in response to radiation. This results in
increased radiation sensitivity as evidenced by decreased clono-
genic survival. Our data implicate NHEJ inhibition as a potential
therapeutic approach in PDAC.
Results
Basal DNA damage in PDAC
In an effort to understand why PDAC are profoundly resistant
to DNA damaging therapies, such as cytotoxic chemotherapy and
radiation therapy, we undertook an effort to understand the DNA
damage response and DNA repair in these tumors. As an initial
step, basal levels of DNA damage were examined in a collection of
18 PDAC cell lines as well as a non-transformed immortalized
human pancreatic ductal cell line (HPDE) [17] as a control.
Western blot analysis for cH2AX, a widely used marker for DNA
damage, particularly DNA double strand breaks (DSBs) [18,19]
was performed. Strikingly, more than half of the PDAC cell lines
showed elevated levels of cH2AX (Figure 1A and 1B) compared to
HPDE. To confirm that the elevated levels of cH2AX were not
merely due to increased levels of total histones, we normalized the
levels of cH2AX to total H2AX in selected cells lines (data not
shown) and demonstrated that these lines continued to have
elevated cH2AX compared to HPDE cells. As further evidence of
the elevated DNA damage in PDAC, cH2AX immunofluores-
cence was performed in representative PDAC cell lines. These
analyses were largely consistent with the western blot data, with
foci in PDAC lines typically higher than in HPDE (Figure 1C
and 1D). To directly measure DNA damage, neutral comet assays
were performed to evaluate the amount of double-strand breaks
under basal conditions. Again consistent with the cH2AX data,
four of the five PDAC cell lines assayed demonstrated statistically
higher tail moments than that in HPDE (Figure 1E), indicating
increased DSBs. Taken together, these data indicate that PDAC
cells often possess elevated basal levels of DNA damage which may
result in activation of a DNA damage response.
DNA Repair Pathways in PDAC
The two major DNA repair pathways for double strand break
repair are homologous recombination (HR) and non-homologous
end joining repair. HR repair requires an homologous chromo-
some or a sister chromatid as a template and mainly takes place in
S or G2 phase of cell cycle to precisely repair damaged DNA [7].
NHEJ, however, repairs DNA by directly ligating the DNA ends
after end processing which often introduces loss of nucleotides and
makes NHEJ error-prone [9]. Given the elevated basal levels of
DNA damage in PDAC, we assessed the proficiency of these cells
for HR and NHEJ. To measure the relative amount of HR, we
performed immunofluorescence for Rad51, a critical HR protein
which binds to single-stranded DNA overhangs and catalyzes the
process of DNA strand exchange. The formation of Rad51 foci is
a sensitive and specific indicator of HR [20,21]. Basal levels of
Rad51 foci were low in 8988T PDAC cells as well as in HPDE
cells (Fig 2A). While HPDE cells showed a marked increase in
Rad51 foci with increasing doses of radiation, 8988T cells showed
a significantly lower increase in foci even at 5 Gy of radiation
(Fig 2A). Given the minimal levels of HR seen in this PDAC line,
we speculated that these cells may rely primarily on NHEJ for
repair. To assess NHEJ, we utilized a well characterized luciferase-
based plasmid repair assay [22,23]. In brief, a cut luciferase
plasmid (PGL2) is transfected into cells and repair via NHEJ is
measured by relative luciferase activity. Both 8988T and Panc1
PDAC lines demonstrated proficiency in NHEJ as demonstrated
in Figure 2B.
DNA-PK is required for PDAC growth
Given the results from the DSB repair assays, we next asked
whether PDAC cells rely on NHEJ for normal proliferation and
growth. We focused on inhibition of DNA-PK, which consists of
the Ku70/Ku80 heterodimeric protein and the catalytic subunit,
DNAPKcs, and is essential for NHEJ [24]. Using shRNAs, we
suppressed expression of the regulatory subunits of DNA-PK,
Ku70 and Ku80 in 8988T cells. Both shRNAs produced a robust
decrease of the expression of Ku70 or Ku80 in 8988T cells, which
was detected by qRT-PCR for Ku70 and Ku80 and by western
blot for Ku70 (Figure 3A). Depletion of Ku70 or Ku80
significantly inhibited the anchorage independent growth of
8988T as assessed by softagar assays, as well as proliferation by
growth curve assay (Figure 3B and 3C). Suppression of Ku70 or
Ku80 also decreased the growth rate of two additional PDAC cell
lines, HupT3 and BXPC3 (Figure 3C). In contrast to PDAC,
depletion of Ku70 or Ku80 in HPDE, MCF7 (a breast cancer cell
line) or H460 (a lung cancer cell line) showed more modest effects
on proliferation (Figure 3C). These data suggest that PDAC cells
require Ku70, Ku80 for growth. To further analyze the
requirement of NHEJ to maintain PDAC growth, a pharmacolog-
ical DNA-PK inhibitor, NU7026 [25,26], was used to investigate
the involvement of DNA-PK in PDAC growth. NU7026
treatment significantly decreased the anchorage-independent
growth of PDAC cells, while the growth of H460 and MCF7
was not affected even at the highest doses (20 mM) (Figure 4A).
Additionally, we determined the sensitivities of a collection of
PDAC lines to NU7026 by determining the IC50s (Fig 4C). More
than half of the lines were sensitive to DNA-PK inhibition.
NU7026 also decreased clonogenic survival of 8988T PDAC cells
(Figure 4B). Together, the data support that PDAC cells rely on
NHEJ DNA repair for growth under basal conditions.
One potential outcome, when damaged DNA is left unrepaired
is that cells will eventually undergo apoptosis [27,28]. To assess the
cellular consequences of DNA-PK inhibition on PDAC cells, we
looked at markers of DNA damage and apoptosis after short
(1 day) or long-term (7 days) treatment with NU7026. Indeed, we
found that DNA-PK inhibition for one day caused additional
DNA damage analyzed by cH2AX. However, at the seven day
timepoint, increased cleaved caspase-3 expression became appar-
ent indicating that apoptosis may be elevated in NU7026 treated
cells but not in DMSO treated control cells (Figure 4D). In
contrast, treatment of HPDE cells with NU7026 showed increased
cH2AX with very minimal cleaved caspase-3 expression
(Figure 4E). Thus, inhibition of the NHEJ pathway leads to
a further accumulation of DSBs, checkpoint activation and
ultimately apoptosis in PDAC cells.
DSB repair in PDAC after IR is dependent on DNA-PK
To further explore the response of PDAC cells to DNA damage,
we measured the repair kinetics of three PDAC cell lines following
IR by monitoring cH2AX foci at 30 min, 2, 6 and 12 hours after
IR with a clinically relevant dose of 2Gy. cH2AX foci peaked at
around 30 min after IR. At 12 h post IR, the number of cH2AX
foci in all three PDAC cells returned to basal level. We further
found that the repair of all three PDAC cell lines was significantly
attenuated by inhibition of DNA-PK, indicating that the repair of
DSBs in PDAC cells is highly dependent on NHEJ (Figure 5A).
Interestingly, inhibition of DNA-PK had only a minimal effect on
the repair of HPDE cells (Fig 5A). We next examined how HR
repair was impacted by inhibition of NHEJ. As shown previously,
Pancreatic Cancers Require NHEJ
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However, HR was significantly increased in the presence of
NU7026 in 8988T cells after IR (Figure 5B). Despite the apparent
compensatory increase in HR in 8988T cells where NHEJ is
inhibited, the number of cH2AX foci remains high (Figure 5A),
indicating that this is still not sufficient for complete repair.
NHEJ inhibition sensitizes PDAC to IR
Inhibition of NHEJ increases DNA damage leading to de-
creased growth and apoptosis in PDAC cells, as well as results in
the prolonged presence of DNA damage foci following radiation.
Therefore, NHEJ inhibition would be expected to enhance the
efficacy of radiation. Both 8988T and Panc1 cells showed
increased sensitivity to IR when they were treated with NU7026
as shown by decreased clonogenic survival (Figure 6A). Similarly,
8988T and Panc1 cells with Ku70 or Ku80 knockdown were also
more sensitive to IR (Figure 6B). Consistent with the decreased
clonogenic cell survival, an increased fraction of 8988T cells were
arrested at the G2/M phase of the cell cycle when cells were
treated with NU7026 and IR (71.88% vs. 27.26% in the irradiated
control) compared to control treated or irradiated cells (Figure 6C).
Discussion
Pancreatic cancers are profoundly resistant to current thera-
peutic approaches, including those that work via inducing DNA
damage such as various cytotoxic chemotherapies and radiation.
Thus, understanding the response of these tumors to DNA
damage may provide key therapeutic insights. Our work
demonstrates that pancreatic cancer cell lines often have elevated
levels of basal DNA damage in the absence of exogenous
damaging agents. While the exact etiology of the increased basal
DNA damage is not known, it is tempting to speculate that the
constant genomic instability that these tumors endure [3] may be
partially responsible. For example, during the process of genomic
amplification, breakage-fusion-bridge cycles occur which result in
Figure 1. Elevated spontaneous DNA damage in PDAC cells. (A) Western blot analysis of cH2AX in HPDE and 18 PDAC cell lines. Samples from
8988T and Panc1 irradiated at 4Gy were used as positive controls and actin served as the loading control. Experiments were done at least three times.
(B) Quantitation of cH2AX expression by densitometry was normalized to actin expression and presented as relative to HPDE. Data is shown from
three independent experiments with error bars representing standard deviations. (C) Immunofluoresence for basal cH2AX foci in three representative
cell lines (HPDE, 8988T and HPAC). Green: cH2AX; Blue: DAPI (nucleus). Scale bar equals 10 mm. Quantitation was performed in (D) and shown as
percentage of cells with more than 5 foci. Experiments were done three times and average values were calculated. Error bars represent standard
deviation from three individual experiments. (E) Neutral comet assay was performed to directly assess DNA double strand breaks and the data
expressed as tail moment (Tail moment=tail length 6% of DNA in the tail). For all panels, asterisks show a statistically significant increase as
compared to HPDE by t-test (p#0.05).
doi:10.1371/journal.pone.0039588.g001
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genomic events frequently seen in PDAC, such as chromosomal
translocations, may promote a steady state of DNA damage.
Our findings also suggest that NHEJ is the major pathway
responsible for DSB repair in pancreatic cancer cells as inhibition
of NHEJ abolishes the rapid repair kinetics. Together, the
evidence would suggest a scenario where these tumors have
developed a reliance on NHEJ to survive continuous genomic
instability and the resultant DNA damage that ensues. The
selection of DSB repair pathway and the relationship between HR
and NHEJ are of great scientific interest and while the exact
molecular underpinnings of pathway selection are being worked
out, it is likely that at least part of the repair choice is dictated by
the cell-cycle, as HR can only function in S/G2/M [7]. We show
that HR is quite low in PDAC cells, even in response to IR.
However, there is a compensatory increase in HR when NHEJ is
inhibited, but, it is insufficient to prevent genotoxic levels of DNA
damage.
Additionally, our results are also in line with the recent
therapeutic approaches in BRCA1 and 2 mutant tumors using
PARP inhibitors. This ‘‘synthetic lethality’’, where tumors with
a single DNA repair pathway such as HR is impaired are sensitive
to inhibition of a second repair pathway (e.g. BER), has received
much attention [30,31,32]. In line with the concept of inhibiting
DNA repair pathways as a therapeutic approach, PDAC show
a sensitivity to NHEJ inhibitors. One potential explanation is that
the elevated basal DNA damage serves to overwhelm the DSB
repair making them susceptible to inhibition of NHEJ or other
DNA repair pathways.
Lastly, inhibition of NHEJ shows a strong synergy with
radiation. This is not unexpected from a mechanistic standpoint,
but may have clinical implications in the treatment of the disease.
While distant disease is a significant cause of mortality in
pancreatic cancer, recent data shows that as many as 30% PDAC
deaths are directly attributable to local progression [33]. Un-
fortunately, surgery is not possible for the majority of these patients
and the only other available local therapy, radiation, is ineffective
in the majority of cases, even when combined with chemotherapy
[34]. Therefore, increasing the sensitivity of these tumors to
radiation could have a transformative impact in this population of
patients. Indeed, the development of inhibitors to DNA repair
proteins is occurring rapidly and many are moving into the clinic
as components of cancer treatment [35]. The mechanistic insights
identified in this study, provide a compelling molecular rationale
to explore the development of such agents for the treatment of
pancreatic cancer.
Materials and Methods
Cell culture and reagents
The human tumor cell lines were obtained from the American
Type Culture Collection or the German Collection of Micro-
organisms and Cell Cultures. HPDE cells were obtained from
M.S. Tsao. [17]. Cells were grown in either DMEM or RPMI
supplemented with 10% cosmic calf serum, antibiotics and
Figure 2. Pancreatic cancers have low levels of HR and are proficient in NHEJ repair. (A) HR in response to increasing doses of radiation (0,
2, and 5 Gy) was measured by Rad51 foci formation and expressed as average foci per cell. Foci are increased in HPDE cells with increasing doses of
radiation, while are only minimally changed in 8988T cells. Data are from two independent experiments performed with replicate coverslips with
error bars representing standard deviations. Asterisks show a statistically significant difference by t-test (p#0.05). Representative images are shown
below. (B) NHEJ measured by a plasmid luciferase repair assay. Data are normalized for transfection efficiency and then to uncut luciferase. Both
Panc1 and 8988T cells show appreciable NHEJ repair. Knockdown of Ku80 markedly decreased NHEJ in Panc1 cells. Error bars represent standard
deviations of three independent experiments.
doi:10.1371/journal.pone.0039588.g002
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time PCR (left) and western blot (right). (B) Upper panel: representative images of soft agar colony formation of 8988T cells infected with either
a control shRNA to GFP or two different shRNAs to Ku70 or Ku80 respectively. Lower panel: quantitation of soft agar colony formation of 8988T cells
relative to shGFP infected cells. Results are averages of three independent experiments and error bars represent standard deviations. Two asterisks
Pancreatic Cancers Require NHEJ
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(KSF) medium supplemented by bovine pituitary extract and
epidermal growth factor (Gibco). NU7026 (Sigma) was used at
20 mM unless otherwise noted.
Real-time PCR
The RNA was isolated with TRIzol (Invitrogen), DNase-treated
and reverse transcribed to cDNA using MMLV High Performance
Reverse Transcriptase (Epicentri) following the manufacturer’s
indicate statistical significance: P,0.01 by t-test (C) Growth curve assays were performed to assess the effect of inhibition of NHEJ by Ku70 and Ku80
knockdown on PDAC growth. Note the robust suppression of growth in PDAC cell lines (8988T, HupT3, BXPC3) and only modest effects on other cell
lines (MCF7, H460 and HPDE).
doi:10.1371/journal.pone.0039588.g003
Figure 4. Pharmacologic Inhibition of NHEJ impairs PDAC growth. (A) Soft agar assays in 8988T PDAC cells and tumor cell lines of other
histologies (H460 and MCF7) with increasing doses of the DNA-PK inhibitor NU7026 demonstrates the dose-dependent inhibition of anchorage-
independent growth in PDAC cells but only minimal effects in the other cell lines assayed. Asterisks show a statistically significant difference by t-test
(p#0.05). (B) Clonogenic survival of 8988T cells treated with NU7026 showing decreased clonogenic growth. (C) IC50s to NU7026 across a larger
panel of PDAC cell lines show the majority are sensitive to DNA-PK inhibition. Error bars represent standard deviations from three independent
experiments. (D) NU7026 treatment of 8988T cells induced DNA damage and apoptosis measured by cH2AX and cleaved caspase-3 respectively.
8988T cells were treated with NU7026 or DMSO as a control for one day or seven days followed by western blot analysis. Increased DNA damage was
seen at the early (Day 1) timepoint with increasing damage and ultimately apoptosis seen on day 7. (E) HPDE cells in comparison show a small
increase in cH2AX expression, but very minimal increase in cleaved caspase-3.
doi:10.1371/journal.pone.0039588.g004
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reagent (Applied Biosystems) in a Bio-Rad Chromo4 Thermo-
cycler. PCR amplification was performed at 95uC for 2 min
followed by 40 cycles of 95uC for 15 sec, 55uC for 15 sec and
72uC for 30 sec. Finally a melting curve was generated from 55uC
to 95uC, read every 0.5uC. The primers were as follows: Ku70,
forward 59- AGTCATATTACAAAACCGAGGGC -39 and re-
verse 59- CCTTGGAGGCATCAACCAAAAA -39 Ku80 forward
59- CCTTTCTGGTGGGGATCAGTA -39 and reverse 59-
ACCTGGTTGGATTTTGCTTTCAA -39.
IC50 assay
Cells were plated in 96-well plates and treated by serial dilution
of NU7026 the next day for 72 h. Cell viability was measured
using the Cell-Titer-Glow assay (Promega, G7570) according to
the manufacturer’s instructions. The IC50 was calculated using
a sigmoidal model using BioDataFit 1.
shRNA transfection
pLKO.1 plasmids containing shRNA sequence for Ku70 and
Ku80 were obtained from The RNAi Consortium (sequences
available upon request). Lentivirus containing Ku70, Ku80 and
GFP control shRNAs were produced in HEK293T packaging cells
and used to infect cells in the presence of 8 mg/ml polybrene
(Sigma H9268). Upon puromycin selection for 2–3 days, cells were
returned to regular medium for experiments.
Cell proliferation assay
Cells infected by lentivirus containing shGFP, shKu70 and
shKu80 were seeded in triplicate in 24-well plates at 2500–5000
cells per well. Cells were fixed in 10% formalin and stained with
0.1% crystal violet on the day as indicated. Dye was extracted with
10% acetic acid and the proliferation was determined by
measuring OD at 595 nm. Relative proliferation was calculated
by normalization to day 0.
Soft agar assay
2 mL of medium containing 1% agarose (Nobel Agar, BD
214230) was placed in 6-well plates as bottom layer. 2 mL of cell
suspension with 5000 cells in medium containing 0.5% agarose
was placed on top of solidified bottom layer. After 9–14 days,
colonies were stained with p-iodonitrotetrazolium violet (Sigma,
18377), counted and photographed. If needed, NU7026 was
added to both the bottom and top agar before being placed in the
Figure 5. Double Strand Break (DSB) repair in PDAC cells is attenuated by NHEJ inhibition. (A) Repair kinetics of three PDAC cell lines
(8988T, Panc1 and BXPC3) were measured by cH2AX staining at various time points after radiation. Data is shown as foci number per cell, normalized
to the 30 min timepoint when foci formation was maximal. Each cell line was treated with NU7026 (20 mM) or DMSO. In each line the resolution of
foci was substantially delayed with NU7026 treatment. Similar experiments were performed in HPDE cells (right panel). Note that the NU7026 does
not attenuate foci resolution in these cells. (B) HR is increased as a compensatory response to NHEJ inhibition in PDAC cells. Rad51 foci formation is
markedly increased when DNA-PK activity is inhibited by NU7026. Left panel: Rad51 foci in green and nucleus in blue shown by DAPI staining. Right
panel: quantitation of foci per cell at the indicated conditions. Data is shown from two independent experiments with error bars representing
standard deviations of the mean.
doi:10.1371/journal.pone.0039588.g005
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top every 3 days. For RNAi experiments, cells were seeded two
days after transfection.
Clonogenic survival assay
Cells were seeded in triplicate in 6-well plates at 100 cells/ well
in growth medium, treated with NU7026 the next day, and
radiated at 2, 4 and 6 Gy. After 10–14 day incubation, cells were
fixed in 80% methanol and stained with 0.2% crystal violet and
colonies were counted. The surviving fraction was calculated using
the plating efficiency.
Neutral comet assays
Neutral comet assays were performed according to the
manufacturer’s instructions (Trevigen). Briefly, cells were com-
bined with low-melting agarose (catalog no. 4250–050–02), and
then mounted on CometSlide (catalog no. 4250–200–03).
Following cell lysis (catalog no. 4250–050–01) and unwinding of
DNA, the cells were electrophoresed for 40 min at 21 volts in TBE
buffer. Slides were fixed with ethanol, stained by SYBR and
images taken by AutoComet machine (TriTek Corp). Minimal
one-hundred randomly selected cells from each sample were
analyzed using CometScore software (http://autocomet.com).
DNA damage was determined by tail moment (tail length
multiplied by the percentage of DNA in the tail).
Western blot analysis
Cells were washed by PBS, counted and lysed in 2x SDS
loading buffer. Western blot analysis was performed according to
standard protocols. The following antibodies were used for
Western: Actin (Sigma, A2066), cH2AX (Millipore, 05–636),
Ku-70 goat (Santa Cruz, sc-1487), Phospho-Chk1 (S345) (cell
signaling, #2348), and Cleaved caspase-3 (Asp175) (cell signaling,
#9664).
Immunofluorescent staining
Cells grown on coverslips or 8-well microscopy slides were fixed
for 20 min with 4% paraformaldehyde and permeabilized by
0.1% Triton X-100 for 3 min. Cells were then incubated
overnight at 4 degrees with mouse monoclonal antibodies against
cH2AX (Millipore, 05–636), or Rad51 (Santa Cruz, sc-8349, H-
92) followed by goat anti-mouse IgG-FITC (Santa Cruz, 1:300) or
goat anti-rabbit IgG-FITC (Santa Cruz, 1:300). Cell images were
taken under a Zeiss microscope using a 63x objective and analyzed
for foci/nucleus.
In vitro pGL2 plasmid –based NHEJ assay
pGL2-control plasmid (Promega) was completely linearized by
the restriction endonuclease HindIII and the linearized DNA was
extracted from agarose gel with Gel Extraction kit (Invitrogen).
Circular plasmid and linearized DNA was then co-transfected with
pRT-RL plasmid into cells with Lipofectamine 2000 (Invitrogen,
11668). The transfected cells were lysed and assayed for luciferase
activity with Dual Luciferase Assay (Promega). The firefly signal
was normalized to that of Renila which served as a transfection
reference. Overall NHEJ capacity was calculated by firefly
luciferase activity from cells transfected with HindIII-digested
DNA relative to that of the intact plasmid.
Flow cytometry assay
Cells were plated in 6-well plates, treated with NU7026 the
following day for 48 hours, and radiated at 2 Gy and fixed after
24 hour with ice cold 70% ethanol in PBS for overnight. After
centrifugation, pellets were resuspended in PBS, stained with
propidium iodide solution for 30 min and analyzed by flow
cytometry (BD FACS Calibur) in the dark.
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